Skip to main content

Table 2 Clinical parameters

From: Genome-wide DNA methylation profiling is able to identify prefibrotic PMF cases at risk for progression to myelofibrosis

 

Progression to fibrosis (FP)

Stable disease (SD)

n = 16

n = 20

Females

6 (38%)

11 (55%)

Age (at diagnosis, mean)

62 years

56 years

Total follow-up

75.5 years

154 years

Range

1.0–12.5 years

4.0–14.0 years

Mean follow-up

5 years

7.3 years

Hemoglobin (g/dL, median)

11.7

14.8

Leukocytes (× 106 × L−1)

16.5

9.2

Thrombocytes (× 109 × L−1)

776

912

Spleen size (mean)

13.4 cm

14.3